Uveitis in Behcet disease-an update

Purpose of review Uveitis is a major manifestation of Behcet disease (BD) and potentially has a high morbidity. This article reviews recently published data on BD uveitis. Recent findings A set of classification criteria and a diagnostic algorithm have been developed for BD uveitis. Recent reports have confirmed male predominance and posterior segment inflammation in the majority of BD uveitis patients. A high uveitis attack severity score, fluorescein angiographic leakage at the posterior pole, and disruption of outer retinal layers on optical coherence tomography (OCT) predict poor visual outcome. OCT-angiography studies have suggested subclinical changes of retinal capillaries in patients with or without ocular involvement. In a randomized controlled trial, interferon-alpha was superior to cyclosporine. Favorable outcomes were reported with earlier initiation, optimization, and withdrawal of infliximab after remission. Adalimumab as first-line was superior to conventional therapy. Summary Classification criteria will be used to select a homogeneous group of patients for research and the diagnostic algorithm may help ophthalmologists predict the probability of BD uveitis based on ocular findings. Fluorescein angiography and OCT are the routine imaging modalities. Clinical relevance of OCT-angiography is unclear. Interferon-alpha, infliximab, and adalimumab have proven superior efficacy compared to conventional therapy.

Automated summary

This article reviews recently published data on Behcet disease (BD) uveitis, including the development of classification criteria and a diagnostic algorithm. It confirms the male predominance and posterior segment inflammation in the majority of BD uveitis patients, as well as the predictive factors for poor visual outcome. The article also highlights the efficacy of interferon-alpha, infliximab, and adalimumab compared to conventional therapy.